On January 8, 2016 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, reported that the Company will present an overview of their CAR-T immuno-oncology clinical development programs at the Biotech Showcase 2016, taking place in San Francisco, CA, on January 11–13, 2016 (Press release, Cellular Biomedicine Group, JAN 8, 2016, View Source [SID:1234508701]). As previously announced the Company will also at that time release 48-week clinical data from the Phase IIb trial of its ReJoin human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The presentations can be viewed via live webcast at the link provided below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: 8th Annual BioTech Showcase 2016
Date: Tuesday, January 12, 2016
Time: 10:00 – 10:30 AM PDT
Title: Alteration of Knee Osteoarthritis, ReJoin Phase IIb One Year Follow Up Results and CAR-T immuno-oncology clinical development program
Location: Track C – Mission II, 4th Flr, Parc 55, Union Square, 55 Cyril Magnin Street, San Francisco, CA
Live webcast: View Source